Plain-English translation of NCT05895825 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called designed to treat advanced solid tumors. Researchers want to find the safest and most effective doses of this treatment, and also understand how food affects how your body processes the medication. You would receive gradually increasing doses of the medication and be closely monitored for safety.
Advanced cancers that have stopped responding to standard treatments leave patients with limited options. This trial exists to see whether this medication could be a new treatment option and to understand the best way for patients to take it.
In Part 1, you would visit the research center to receive gradually increasing doses of the medication as a tablet by mouth, with careful safety monitoring between dose increases. In Part 2, you would take single doses of the medication under different conditions—once while fasting and once after eating a meal—to help researchers understand how food affects the treatment. You would continue receiving the medication as long as it is helping and you are tolerating it well, until the cancer progresses, side effects become too serious, or other stopping criteria are met.
AI-generated summary from trial data · Sep 3, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd
Enrollment target
~48 participants
Started
July 2023
Primary completion
April 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in November 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Binghe Xu, MD
Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd